Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022).

"We have been able to show a correlation between patient survival and a measure of the cumulative potency of PROVENGE; such a correlation between product potency and clinical outcome has not been previously demonstrated with an active immunotherapy," said Mark Frohlich, MD, chief medical officer of Dendreon. "These data provide further evidence that sipuleucel-T is actively engaging the immune system in a clinically meaningful way that prolongs patient survival."

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease. Currently, there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... 2011 In conjunction with its first quarter 2011 earnings ... 4, 2011), Covance Inc. (NYSE: CVD ) is ... conference call that will be broadcast live over the Internet ... Covance First Quarter 2011 Earnings Webcast and Slide PresentationWhen: , ...
... Aribex®, Inc., the worldwide leader in handheld x-ray technologies, has ... premier Practice Management System for dental clinics, to contribute up ... the earthquake and tsunami in Japan. The first two kits ... of the most damaged areas. Each kit will ...
Cached Medicine Technology:Aribex and IDENS Donate 15 Victim I.D. Kits for Japan 2
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, MyDressCity.com, ... and women’s special occasion outfits, has released its new ... all the new products are available at discounted prices. ... 26, 2014. , In the company’s online shop, ... all of them are made with great materials. MyDressCity.com’s ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... RESEARCH TRIANGLE PARK, N.C., May 27 Family,Health ... the,organization will introduce a number of new publications ... 27-31, 2008, at the,Omni Shoreham Hotel in Washington, ... on topics including the public health,impact of the ...
... New technology from Varian Medical Systems delivers faster image-guided,intensity-modulated radiotherapy (IMRT) ... ... healthy tissue, PLANO, Texas, May 27 Earlier this ... medical center in the United States to commence treating cancer,patients with ...
... called flavanols may be responsible for the benefit, study says ... about chocolate being good for your health is starting to ... a scientific division. , And a group of researchers, some ... Symbioscience, has just published a report showing that an enriched ...
... Christine Jacobs-Wagner has been designated an investigator of ... medical research organization that is one of the ... Associate Professor of Molecular, Cellular and Developmental Biology, ... hold the prestigious appointment. HHMI was founded to ...
... GOCE. The change of date is due to precautionary ... of a Russian Proton launcher. Now confirmed not to ... to date is scheduled for lift-off on 10 September ... date, the Gravity field and steady-state Ocean Circulation Explorer ...
... World No Tobacco Day, 31 May, the,International Union Against ... a comprehensive ban on all forms of,advertising, promotion and ... smoking before the age of 18. Almost one,fourth begin ... they first,try smoking, the more likely they are to ...
Cached Medicine News:Health News:Family Health International Featured at Global Health Council Conference 2Health News:Family Health International Featured at Global Health Council Conference 3Health News:Family Health International Featured at Global Health Council Conference 4Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 2Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 3Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 4Health News:Enriched Cocoa Improves Blood Flow in Diabetics 2Health News:Enriched Cocoa Improves Blood Flow in Diabetics 3Health News:Jacobs-Wagner named Howard Hughes Investigator 2Health News:September launch for ESA's gravity mission GOCE 2Health News:September launch for ESA's gravity mission GOCE 3Health News:World No Tobacco Day: Global Organizations Join Forces To Break the Tobacco Marketing Net and Help Children Grow Up Smoke-Free 2
... Filter Units,Filter units with hydrophobic PTFE ... membrane are ideal for the sterilizing ... sterile containers, and for sterilizing or ... mm Millex filter units are available ...
... -4C. 5.5 Cubic Ft. ... light. Manual push button ... Two shelves. In-door shelves ... thermostat. Magnetic gasket. Hermetically ...
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
Medicine Products: